Abstract: The present invention provides a stable, aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base. The invention also provides a method of treating the septic shock by intravenous administration of stable aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base.

Abstract: The present invention provides a stable, aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base. The invention also provides a method of treating the septic shock by intravenous administration of stable aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base.

Abstract: The present invention provides a stable, aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base. The invention also provides a method of treating the septic shock by intravenous administration of stable aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base.

Abstract: The present invention relates to a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is present in an injection device.

Abstract: The present invention relates to a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is present in an injection device.

Abstract: The present invention relates to a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is present in an injection device.

Abstract: The present invention implements structures and method for non-delayed clock dynamic logic circuit configurations with output and/or complementary output with reduced glitch and/or mitigating adverse charge-sharing effects for Complementary Oxide Semiconductor (CMOS) and/or mitigating parasitic bipolar action in Strained/Unstrained Silicon-On-Insulator (SOI) circuits, where insulator may be oxide, nitride of Silicon and the like or Sapphire and the like including a method of synthesis.

Abstract: An improved bicarbonate determination with variability of apparent dissociation constant in Henderson-Hasselbach equation or Henderson equation with Henry's law is described. The improved bicarbonate is utilized in the determination of improved Base Excess, Base Deficit or Buffer Base for blood gas testing.

Abstract: An improved bicarbonate determination with variability of apparent dissociation constant in Henderson-Hasselbach equation or Henderson equation with Henry's law is described. The improved bicarbonate is utilized in the determination of improved Strong Ion Difference (SID) and Strong Ion Difference Excess (SIDE) as the change in SID from the reference value at pH=7.4, pCO2=5.33 Kpa (or 40 torr) for blood gas testing.

Abstract: The present invention pertains to automated technology dependent transformations for CMOS digital design synthesis resulting in a combination of CMOS interconnected standard-cells from a target CMOS library being mapped and transistor-level representation for all or portion of the input design specification, the transistor level type and portion or portions to be represented at the transistor level representation being chosen by a user, transistor sizing and evaluating the combination of said transistor-level representation and standard-cell mapping iteratively to meet delay, size and power constraints for CMOS.